Trial Profile
Active-Controlled Trial of the Safety and Tolerability of a MP03-33 in Patients With Chronic Allergic or Nonallergic Rhinitis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Aug 2019
Price :
$35
*
At a glance
- Drugs Azelastine (Primary)
- Indications Perennial allergic rhinitis; Vasomotor rhinitis
- Focus Adverse reactions
- Sponsors Meda Pharmaceuticals
- 23 Nov 2008 New trial record.